Heart failure (HF) is characterized by markedly compromised cardiac function, high rate of complications, and decreased life expectancy.
1 Impaired cardiac function and neurohumoral activation are the defining characteristics of HF that contribute to clinical deterioration, and the focus of interventions has generally been on improving circulatory function and on blocking the renin-angiotensin and sympathetic nervous systems.
2 Depression is widely considered a significant psychosocial risk factor in patients with coronary heart disease.
3 Depression is associated with a substantially increased risk of developing HF in individuals at risk
4 and has been associated with adverse outcomes in patients with established HF. In a study by Jiang et al
5 of 374 hospitalized patients with HF who underwent screening for depression, those with major depression were approximately twice as likely to die or be rehospitalized within 1 year. Similarly, Vaccarino et al
6 reported that severity of depressive symptoms was related to death or functional decline at 6-month follow-up in 391 hospitalized patients with HF. Murberg and Furze
7 recently reported findings of 6-year follow-up in 119 patients with HF in whom symptoms of depression at baseline were predictive of death. Because depression in patients with HF is related to disease severity, however, there remains uncertainty about the extent to which depression, independent of HF severity, is related to adverse clinical outcomes.
8 In the last few years, B-type natriuretic peptide (BNP) and
N-terminal proBNP (NT-proBNP), which are released from the cardiac ventricles and have vasodilator and diuretic effects, have emerged as standard diagnostic and prognostic markers of HF.
9,10 In the present prospective study of 204 outpatients with HF, we used NT-proBNP to adjust for HF severity in evaluating whether symptoms of depression were related to death and hospitalizations during 3 years of follow-up.